Keros Therapeutics, Inc. (KROS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Keros Therapeutics, Inc. (KROS)
Company Performance

Current Price

as of Oct 16, 2024

$62.18

P/E Ratio

N/A

Market Cap

$2.33B

Description

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Metrics

Overview

  • HQLexington, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerKROS
  • Price$62.18+2.96%

Trading Information

  • Market Cap$2.33B
  • Float79.53%
  • Average Daily Volume (1m)366,470
  • Average Daily Volume (3m)339,877
  • EPS-$5.13

Company

  • Revenue$0.27M
  • Rev Growth (1yr)N/A
  • Net Income-$45.26M
  • Gross Margin-727.03%
  • EBITDA Margin-135,494.59%
  • EBITDA-$50.13M
  • EV$1.26B
  • EV/Revenue4,642.10
  • P/EN/A
  • P/S8,283.75
  • P/B5.34
Documents
SEC Filings
8-K (2024-10-16)
8-K (2024-09-30)
8-K (2024-09-03)
8-K (2024-08-28)
8-K (2024-08-07)
8-K (2024-06-17)
8-K (2024-06-04)
8-K (2024-06-03)
8-K (2024-05-30)
8-K (2024-05-28)
8-K (2024-05-08)
8-K (2024-03-14)
8-K (2024-03-06)
8-K (2024-03-05)
8-K (2024-02-28)
8-K (2024-01-09)
8-K (2024-01-04)
8-K (2024-01-03)
8-K (2023-12-11)
8-K (2023-11-07)
8-K (2023-11-06)
8-K (2023-10-04)
8-K (2023-09-05)
8-K (2023-08-07)
8-K (2023-07-24)
8-K (2023-06-09)
8-K (2023-06-07)
8-K (2023-06-06)
8-K (2023-05-22)
8-K (2023-05-04)
8-K (2023-04-19)
8-K (2023-03-03)
8-K (2023-03-01)
8-K (2023-02-07)
8-K (2023-01-09)
8-K (2023-01-06)
10-Q (2024-08-07)
10-Q (2024-05-08)
10-Q (2023-11-06)
10-Q (2023-08-07)
10-Q (2023-05-04)
10-K (2024-02-28)
10-K (2023-03-03)
Factset Street Account
Keros Therapeutics reports Q3 EPS ($1.33) vs FactSet ($1.35) [9 est, ($1.46)-(1.27)] ($31.94, 0.00) (2023-11-06T13:06:19Z)